Oncoseek Bio receives investments and support from USISTEF, DBT and friends & family.
Oncoseek Bio is in association with three hospitals to make translational research useful for the patients.
UoH’s BioNEST has been selected as the best emerging bio-incubator, Oncoseek Bio is incubated here.
06th March 2021Oncoseek Bio Pvt Ltd, one of the start-up companies of ASPIRE-BioNEST at University of Hyderabad (UoH) has received the U.S.–India Science & Technology Endowment Fund (USISTEF) under Covid-19 Ignition Grants for a “Novel therapeutic strategy to fight against Covid-19”
This project was one of the 11 selected out of 520 proposals that were received and evaluated. This is the second competitive grant that the company is receiving. Earlier it has received a grant from BIRAC, Govt. of India to develop a platform to screen the potential drug candidates for Covid-19.
UoH incubated startup Oncoseek Bio bags grant for Covid-19 research
08th September 2020Oncoseek Bio Pvt Ltd, one of the start-up companies of ASPIRE-BioNEST at University of Hyderabad (UoH) has received the U.S.–India Science & Technology Endowment Fund (USISTEF) under Covid-19 Ignition Grants for a “Novel therapeutic strategy to fight against Covid-19”
This project was one of the 11 selected out of 520 proposals that were received and evaluated. This is the second competitive grant that the company is receiving. Earlier it has received a grant from BIRAC, Govt. of India to develop a platform to screen the potential drug candidates for Covid-19.
USISTEF Covid-19 challenge grant for UoH start-up Oncoseek Bio
08th September 2020The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has resulted in a global health and economic crisis of unprecedented scale. The high transmissibility of SARS- CoV-2, combined with a lack of population immunity and prevalence of severe clinical outcomes, urges the rapid development of effective therapeutic counter measures. To combat this pandemic and in keeping with its mission and vision, the U.S.–India Science & Technology Endowment Fund (USISTEF) announced a call for proposals under the category of COVID-19 Ignition Grants in April 2020. After a rigorous binational review process, USISTEF announced awards to 11 bilateral teams, proposing out-of-the-box, innovative ideas that address the COVID-19 challenge.
UoH Startup bags grant from US-India R&D fund
08th September 2020A start-up company incubated at the University of Hyderabad (UoH) has won a US-India Science and Technology Endowment Fund (USISTEF) ignition grant for its "Novel therapeutic strategy to fight against Covid-19". The proposal by Novel Oncoseek Bio Pvt Ltd., was one of the eleven that were selected from 520 proposals that were received and evaluated. The company is one of the start-up companies of ASPIRE-BioNEST at UoH had earlier received a grant from BIRAC, Government of India to develop a platform to screen the potential drug candidates for Covid-19.
UoH start-up gets US-India science grant for Covid
08th September 2020Oncoseek Bio Pvt Ltd, one of the start-up companies of ASPIRE-BioNEST at University of Hyderabad (UoH) has received the US–India Science and Technology Endowment Fund (USISTEF) under Covid-19 Ignition Grants for a “Novel therapeutic strategy to fight against Covid-19”.
UoH start-up bags Covid-19 challenge grant from USISTEF
08th September 2020Start-up company incubated at the University of Hyderabad (UoH) has won a US-India Science and Technology Endowment Fund (USISTEF) ignition grant for its "Novel therapeutic strategy to fight against Covid-19".The proposal by Novel Oncoseek Bio Pvt Ltd., was one of the eleven that were selected from 520 proposals that were received and evaluated.
Star-tup at Hyderabad University receives USISTEF fund to develop therapeutically COVID-19
08th September 2020A start-up incubated at the University of Hyderabad has received the United States India Science and Technology Fund (USISTEF) under the COVID-19 inflammatory awards for a new therapeutic strategy to fight the virus. Oncoseek Bio Pvt. Ltd., one of the start-ups of UoH’s ASPIRE-BioNEST incubators, was one of 11 out of 520 proposals selected for the fund.
This is the second competitive award the company has received. Earlier, it received an award from BIRAC, Govt. of India, to develop a platform to investigate the potential drug candidates for Covid 19. Oncoseekbio Pvt Ltd, which has been with ASPIRE-BioNEST since 2019, has a vision to develop in vitro and in vivo platforms for specific therapeutic screening diseases.
BIRAC To Invest In OncoSeek Bio For Facilitating Covid-19 Cure
29th April 2020Hyderabad-based biotech startup OncoSeek Bio has been selected for funding from the state-run Biotechnology Industry Research Assistance Council (BIRAC) for developing a potential cure for the Covid-19 virus.
Incubated at the University of Hyderabad (UoH), OncoSeek Bio will develop an in vitro lung organoids. These organoids are simply a 3D tissue-engineered mini lung which has the capacity to replicate the aspects of lung tissues. Organoids can help researchers to find drugs for better treatment of Covid-19.
Hyderabad startup bags BIRAC funding for Covid-19 project
27th April 2020In a boost to efforts aimed at tackling the pandemic, a start-up incubated at the University of Hyderabad (UoH) has been selected for Covid-19 funding by the Biotechnology Industry Research Assistance Council (BIRAC).
OncoSeek Bio Pvt Ltd will receive funding support for developing an in vitro Lung Organoid model, from BIRAC which comes under the Union Science and Technology Ministry's Department of Biotechnology (DBT).
UoH-incubated firm gets DBT funding
27th April 2020A startup incubated at the University of Hyderabad (UoH) has been selected for financial support for developing an ‘in vitro lung organoid model’.
“Current animal models available for research on COVID-19 are either difficult to get into India or create them in time, to address the pandemic. The company envisages creating novel in vitro platforms for the research under the support,” said founder-CEO of OncoSeek Bio Pvt. Ltd., Suresh Poosala, on Sunday.
UoH incubated startup to receive Birac funding
27th April 2020OncoSeek Bio Pvt Ltd, an incubated startup of University of Hyderabad (UoH), has been selected for Covid-19 funding by Biotechnology Industry Research Assistance Council (Birac).
According to a press release issued by UoH, the startup has been selected for financial support to develop an in vitro lung organoid model. OncoSeek Bio is one of the 16 projects of the 500 proposals received by the Birac under the department of biotechnology (DBT) for funding support for the Covid-19 research consortium.
For More articles check below links
27th April 2020
The News Minute: University of Hyderabad start-up wins BIRAC funding for Covid-19 project
Andhram News: University of Hyderabad start-up wins BIRAC funding for Covid-19 project
Delhipost News: Dept of Biotech to support several projects to fight COVID-19
Mathrubumhi News: University of Hyderabad start-up wins BIRAC funding for COVID-19 project
Telangana Today: UoH startup selected for funding to develop in-vitro lung organoid model
Republic World: UoH startup selected for funding to develop in-vitro lung organoid modelUoH start-up OncoSeek Bio to receive BIRAC funding for COVID-19 project
Outlook: Govt seeks proposals on vaccines development, diagnostics
The New Indian Express: Hyderabad emerges as top COVID-19 research destination
MSN News: 16 contenders shortlisted for India’s corona vaccine effort
UoH Herald: UoH Startup selected for Covid-19 funding by BIRAC
Eenadu: UoH Startup selected for Covid-19 funding by BIRAC
ANI News: UoH Startup selected for Covid-19 funding by BIRAC
Transtoxbio portfolio finds client in OncoSeek Bio Pvt. Ltd.’s preclinical Discovery and Services
6th March-2020TranscellOncologics’s cell based platforms portfolio,Transtoxbio, inks an agreement with OncoSeek Bio Pvt. Ltd (OSB), a Hyderabad based boutique Contract Research Organization.

As part of this engagement OSB sources various cells and cellular platforms from Transtoxbio portfolio to enable its in-house exploratory R&D, discovery and screening on novel platforms that use various monolayers or 3D structures including spheroids/organoids/microfluidics and other printed technologies. OSB also plans to use Transtoxbio’s new league of human sourced primary mature cells and primary stem cells (CD34+ cells - TRANS-HSC) in generating new relevant animal models for several disease conditions that have no true preclinical animal model representation currently for pharmaceutical research. OSB is keen to treat Transtoxbio portfolio as itsmain cell based platforms or free suspended cells supplier for all its preclinical models and services to be offered to global industry and for its own discovery programs.